Were You Sold Asterias Biotherapeutics, Inc. (AST) By a Broker from Laidlaw and Company?

Soreide Law Group has been contacted by clients who purchased Asterias Biotherapeutics, Inc. (AST) and experienced stock losses.  Not only were the brokers from Laidlaw and Company offering this stock, but Laidlaw also served as the underwriter of the offering. Securities that are newly issued are typically more volatile than the older more established companies, and if an investor was not looking to speculate, this may have been an unsuitable recommendation to you by your broker/dealer from Laidlaw and Company.
According to Yahoo Finance, Asterias Biotherapeutics, Inc. (AST), is a clinical-stage biotechnology company, which focuses on developing cell-based therapeutics to treat neurological conditions associated with demyelination, and cellular immunotherapies to treat cancer. The company was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. Asterias Biotherapeutics, Inc. was founded in 2012 and is headquartered in Fremont, California.
In June of 2012, AST was trading around 45.45, and today AST is trading at approximately 1.71. The 52-week change for AST is -43.75%.
Laidlaw and Company’s website lists the following information on their company, ”Our team of bankers’ focus on the healthcare industry and the depth of their experience allows them to provide comprehensive knowledge of both the industry and the markets.”
If you’ve experienced investment losses in Asterias Biotherapeutics, Inc. (AST) due to the recommendations of a Laidlaw and Company securities broker, call Soreide Law Group for a no cost consultation with an experienced securities lawyer regarding the possible recovery of your valuable financial losses through a FINRA arbitration at: 888-760-6552.
Soreide Law Group represents clients nationwide before FINRA.  We operate on a contingency fee basis, no fee if no recovery.